Argos Therapeutics, Inc. (ARGS) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $1.14, up from yesterday’s close by 8.57%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Argos Therapeutics, Inc. (ARGS) currently trades with a market capitalization of $4.45 Million. That value represents a market adjusting for revenues that have been growing by 921.11 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of -$39.1 Million over the past twelve months. Generally speaking, earnings are expected to hold steady in coming quarters. Analysts are forecasting earnings of -$1.8 on a per share basis this quarter. Perhaps, that suggests something about why 25.07% of the outstanding share supply is held by institutional investors.
As most professionals know, technical analysis can offer critical insights into what smart money and insiders think about a stock’s prospects going forward. Looking at the stock’s movement on the chart, Argos Therapeutics, Inc. recorded a 52-week high of $16.40. It is now trading 15.26% off that level. The stock is trading $1.26 its 50-day moving average by 0.12%. The stock carved out a 52-week low down at $0.70.
In recent action, Argos Therapeutics, Inc. (ARGS) has made a move of -8.06% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 13.41, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 19.29% with $3.36 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ARGS.